Tag Archive for: #parkinsonsdisease

Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325

/in

MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place in UK, Europe and Australia – will assess MTX325’s clinical proof-of-mechanism, safety and tolerability in 36 patients with mild to moderate Parkinson’s disease Comes after successful […]

Read more

Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

/in

• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function • MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently • Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech […]

Read more

BioInnovation Institute provides financial support as six promising companies enter the Venture House program

/in

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that six companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth. Read more…

Read more

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

/in

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York. Dr […]

Read more

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

/in

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York. Read […]

Read more
© Optimum Strategic Communications.